BioSpace News Archive

Trevi Therapeutics, Inc. today announced data will be presented from two scientific abstracts on the phase 2 CANAL trial in IPF chronic cough at the ATS 2023 International Conference, organized by the American Thoracic Society, being held in Washington, D.C. from May 19-24. The oral presentations will take place on May 22.

GlycoEra AG announced today that Santiago Arroyo , MD has been appointed to its Board of Directors.

Repligen Corporation today reported financial results for its first fiscal quarter ended March 31, 2023.

Savaria Corporation (“Savaria”) (TSX: SIS) one of the global leaders in the accessibility industry, announces it will release its financial results for the first quarter of 2023 after market close on May 10, 2023.

CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that members of its senior management team are scheduled to participate in fireside chats at the following investor conferences in May.

Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, announced that it will present at two upcoming investor conferences.

Amolyt Pharma today announced that it will initiate its Phase 3 clinical trial of eneboparatide, a long-acting parathyroid hormone 1 (PTH1) receptor agonist, in patients with hypoparathyroidism following the receipt of End-of-Phase 2 guidance from the U.S. Food and Drug Administration (FDA).

Protara Therapeutics, Inc. (Nasdaq: TARA) today announced that it has received regulatory clearance from the U.S. Food and Drug Administration (FDA) on its planned Phase 2 STARBORN-1 trial evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of pediatric patients with lymphatic malformations (LMs).

Candel Therapeutics, Inc. (Nasdaq: CADL) today announced an abstract detailing new data from its phase 1 clinical trial of CAN-3110 in patients with recurrent high-grade glioma was accepted as an oral presentation in the upcoming American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting in Los Angeles, CA and virtually, May 16-20, 2023.

BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced its participation in the Annual Meeting of the Clinical TMS Society’s from May 4-6 and the Annual Meeting of the American Psychiatric Association from May 20-24.